Corvus Pharmaceuticals (CRVS) closed at $9.67 on November 20, 2026, down 3.4% from the previous close, on volume of 854,567 shares (30-day average 939,065).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Diagonal Call Spread | 15-Jan : 16-Apr-2715 : 10 C | 234 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
Globe Newswire (Wed, 30-Sep 4:05 PM ET)
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 8:30 AM ET)
Globe Newswire (Thu, 27-Aug 7:30 AM ET)
Market Chameleon (Thu, 14-May 6:37 AM ET)
Soquelitinib Phase 1 Data Shows Durable, Drug-Free Remissions for Atopic Dermatitis Patients
Market Chameleon (Thu, 14-May 3:56 AM ET)
Market Chameleon (Tue, 21-Apr 4:21 AM ET)
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Corvus Pharmaceuticals trades on the NASDAQ stock market under the symbol CRVS.
As of November 20, 2026, CRVS stock price declined to $9.67 with 854,567 million shares trading.
CRVS has a beta of 0.89, meaning it tends to be less sensitive to market movements. CRVS has a correlation of 0.01 to the broad based SPY ETF.
CRVS has a market cap of $815.69 million. This is considered a Small Cap stock.
In the last 3 years, CRVS traded as high as $26.95 and as low as $1.30.
The top ETF exchange traded funds that CRVS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CRVS has outperformed the market in the last year with a return of +13.6%, while the SPY ETF gained +6.9%. However, in the most recent history, CRVS shares have underperformed the stock market with its stock returning -32.5% in the last 3 month period and -8.3% for the last 2 week period, while SPY has returned -9.3% and -6.2%, respectively.
CRVS support price is $9.58 and resistance is $10.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVS shares will trade within this expected range on the day.